Overview
Biorelate uses AI-powered biomedical data curation and analytics with Galactic AI to transform unstructured literature into a knowledge graph by extracting causal relationships among genes, drugs, diseases, and proteins. This curated knowledge supports bespoke data services, direct access to curated data, and cloud-platform licenses for researchers and pharma clients. It differentiates itself by focusing on causal relationships in unstructured data and serving large pharma and biotech firms with tailored services and a commercial-grade platform. Its goal is to accelerate drug discovery and research decisions by expanding high-quality data and tools, and growing its presence in the United States.
Work here?Claim your company
Simplify's take
What believers are saying
- Biorelate raised £2.5 million in August 2026, extending runway for product expansion.
- BiotechX Basel in October 2026 showcased demand for causality-focused R&D tools.
- Pharmaphorum featured Ben Sidders on November 14, 2026, strengthening category credibility.
What critics are saying
- Financial filings showed a £2.9 million loss for year ending March 31, 2025.
- LinkedIn data put headcount near 36, signaling limited scale against bigger rivals SciBite and Averbis.
- If pharma standardizes on foundation-model workflows, Biorelate's curation layer becomes commoditized by 2027.
What makes Biorelate unique
- Galactic AI v3 grounds biomedical AI in citable causal knowledge across 30 million sources.
- Biorelate turns literature, patents, trials, labels, and grants into one ontology-linked graph.
- Its target-safety workflows promise 95% faster assessments with regulatory-grade citations.
Help us improve and share your feedback! Did you find this helpful?